David Sankaran has become chief financial officer and senior vice president of Accelrys, replacing John Hanlon, the San Diego-based company said today. Hanlon will leave Accelrys at the end of the month. Sankaran joins the company from Ocular Sciences, a contact lens manufacturer, where he was vice president and corporate controller. Prior to that, he was vice president of investor relations at PeopleSoft, and before that, vice president and corporate controller for Affymetrix.
Barry Berkowitz has become president and CEO of Scion Pharmaceuticals, replacing Pravin Chaturvedi, who will remain a consultant, the Medford, Mass.-based company said last week. He joins Scion from Albany Molecular Research, where he was corporate vice president. Berkowitz holds a PhD in pharmacology from the University of California, San Francisco, and a BSc in pharmacy from Northwestern University.
Patricia Goldsmith has become senior vice president of business development, public affairs, and policy at the National Comprehensive Cancer Network, NCCN said yesterday. She used to be vice president for institutional development, public affairs, and marketing at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Fla., an NCCN member institution.
Michael Nemzek has joined Velocity11 of Menlo Park, Calif., as vice president of marketing, the company said last week. He previously was general manager of discovery tools at Symyx Technologies. Prior to that, He was an executive with Cellomics; Genosys Biotechnologies, now part of Sigma-Aldrich; Tropix, now part of Applied Biosystems; and EG&G, now part of PerkinElmer.
Tony Hunter, Tony Pawson, and Alexander Levitzki have been jointly awarded the 2005 Wolf Prize in Medicine for their research in cancer development and treatment, the Wolf Foundation said last week. They will equally share the $100,000 prize, which will be presented to them in Jerusalem on May 22.
Hunter, a professor of biology at the Salk Institute, is recognized for discovering tyrosine protein kinases. He holds a PhD from the University of Cambridge, UK. Pawson, a senior scientist at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto and a professor at the University of Toronto, is cited for discovering protein domains essential for mediating protein-protein interactions in cell signaling. He holds a PhD in molecular biology from London University and a BA in biochemistry from Cambridge University. Levitzki is recognized for developing tyrosine kinase inhibitors to treat cancer, paving the way for drugs such as Gleevec. He is a professor of biochemistry at the Hebrew University of Jerusalem. Levitzki holds a PhD in biochemistry and biophysics from Hebrew University and the Weizmann Institute of Science.